Rosetta Genomics Receives First Patent Allowance in Japan

On Feb 10, 2015

Rosetta Genomics Ltd. (with locations in Princeton, New Jersey, and Rehovot, Israel) is a developer and provider of microRNA-based molecular diagnostics.  It announces that is has received a Notice of Allowance from the Japan Patent Office (JPO) for Japanese Patent Application No. 2007-512601, which relates to human miR-92b. The composition of matter patent to be issued claims the sequence of miR-92b and its complement, as well as its use as a probe, including in biochips. miR-92b has been shown to be elevated in cancer and is a key element of the Company’s lead oncology diagnostic, the Rosetta Cancer Origin Test™ (COT).

The claims allowed cover an isolated nucleic acid having the sequence of human miR-92b and its complement, as well as to variants being at least 90 percent identical to miR-92b. In addition, the allowed claims encompass a vector and a probe comprising miR-92b, a composition and a biochip comprising probes specific to miR-92b.

“The extension of our patent protection to cover composition of matter for our oncology diagnostics in Japan demonstrates our commitment to broadly protect our proprietary microRNA technology platform,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “It also supports our comprehensive oncology strategy for the worldwide development and commercialization of microRNA-based diagnostics, therapeutics and biomarkers that can enhance clinicians’ ability to identify and treat cancers and we look forward to monetizing this latest addition to our patent estate through licenses or partnerships in Japan, a significant market for oncology diagnostics and therapeutics.”

“We continue to protect and build upon our leading intellectual property position in microRNA technology and this newly allowed patent expands, strengthens and complements our growing portfolio of over 40 patents worldwide,” added Mr. Berlin.

Related Articles: